Effects of Val-Pro-Pro and Ile-Pro-Pro on nondipper patients: A preliminary study

Journal of Medicinal Food

Volumn 14, Issue 5, 2011, Pages 538-542

  Kurosawa, Mari Takahashi ^a   Nakamura, Yasunori ^a   Yamamoto, Naoyuki ^a   Yamada, Kazuhisa ^a   Iketani, Toshiro ^b  

^a CALPIS Co Ltd   (Japan)

^b Department of Internal Medicine   (Japan)

Author keywords

automatic blood pressure monitoring; dipper; early morning blood pressure; family physician; Ile Pro Pro; nondipper; Val Pro Pro

Indexed keywords

ANTIHYPERTENSIVE AGENT; ISOLEUCYLPROLYLPROLINE; LACTOTRIPEPTIDE; TRIPEPTIDE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ADULT; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MALE; MILK; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES;

EID: 79956116064     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2010.0343     Document Type: Article

References (29)

1. Kannel WB: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-1576. (Pubitemid 26154243)
2. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
3. Fujita H., Yoshikawa M.: LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology 1999;15: 123-127.
4. FitzGerald RJ, Murray BA, Walsh DJ.: Hypotensive peptides from milk proteins. J Nutr 2004;134:980-988.
5. Meisel H, Bockelmann W.: Bioactive peptides encrypted in milk proteins: proteolytic activation and thropho-functional properties. Antonie Van Leeuwenhoek 1999;76:207-215. (Pubitemid 29440728)
6. Nakamura Y, Yamamoto N, Sakai K, Takano T: Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I- converting enzyme. J Dairy Sci 1995;78:1253-1257.
7. Hata Y, Yamamoto N, Ohni M, et al.: A placebo-controlled study of the effects of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996;64:767-771. (Pubitemid 26398281)
8. Mizuno S, Matsuura K, Gotou T, et al.: Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure or mild hypertension. Br J Nutr 2005;94:84-91. (Pubitemid 41357814)
9. Sano J, Ohki K, Higuchi T, et al.: Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food 2005;8:423-430. (Pubitemid 43121892)
10. Seppo L, Jauhiainen T, Poussa T, Korpela R: A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003;77:326-330. (Pubitemid 36133373)
11. Jauhiainen T, Vapaatalo H, Poussa T, et al.: Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 2005;18:1600-1605. (Pubitemid 41814682)
12. Xu JY, Qin LQ, Wang PY, Li W, Chang C: Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition 2008;24:933-940.
13. Boelsma E, Kloek J: Lactotripeptides and antihypertensive effects: a critical review. Br J Nutr 2009;101:776-786.
14. van der Zander K, Jäkel M, Bianco V, Koning MM: Fermented lactotripeptides-containing milk lowers daytime blood pressure in high normal-to-mild hypertensive subjects. J Hum Hypertens 2008;22:804-806.
15. Engberink MF, Schouten EG, Kok FJ, et al.: Lactotripeptides show no effect on human blood pressure: results from a doubleblind randomized controlled trial. J Clin Nutr 2008;51:399-405. (Pubitemid 351159956)
16. Zweiker R, Eber B, Schumacher M, Toplak H, Klein W: " Nondipping" related to cardiovascular events in essential hypertension patients. Acta Med Austiaca 1994;21:86-89. (Pubitemid 24353354)
17. Verdecchia P, Porcellati C, Shilaci G, et al.: Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994;24:793-801. (Pubitemid 24363980)
18. Palatini P, Penzo M, Racioppa A, et al.: Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 1992;152:1855-1860.
19. Germino FW, Neutel J, Nonaka M, Hendler SS: The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives. J Clin Hypertens 2010;12:153-159.
20. Yamasue K, Morikawa N, Mizushima S, Tochikubo O: The blood pressure lowering effect of lactotripeptides and salt intake in 24-h ambulatory blood pressure measurements. Clin Exp Hypertens 2010;32:214-220.
21. Bouhanick B, Chamontin B: Should pulse pressure and day/ nightcariations in blood pressure be seen as independent risk factors requiring correction or simply as markers to be taken into account when evaluating overall vascular risk? Diabetes Metab 2007;33:321-330. (Pubitemid 350026458)
22. Haiying WU, Zhang Y, Huang J, et al.: Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. Hypertens Res 2001: 605-610. (Pubitemid 33048929)
23. Cuspide C, Meani S, Valerio C, Dusi V, Zanchetti A: Nocturnal non-dipping pattern in untreated hypertension at different cardiovascular risk according to the 2003 ESH/ESC guidelines. Blood Press 2006;15:37-44.
24. Higashi Y, Nakayawa K, Noma K, et al.: Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non-dippers. J Am Coll Cardiol 2002;40:2039-2043. (Pubitemid 35425374)
25. Cuspidi C, Michev I, Meani S, et al.: Non-dipper treated hypertensive patients do not have increased cardiac structural alterations. Cardiovasc Ultrasound 2003;1:1-9. (Pubitemid 38870237)
26. Hirota T, Ohki K, Kawagishi R, et al.: Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro- Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 2007;30:489-496. (Pubitemid 47083118)
27. Nakamura T, Mizutani J, Sasaki K, Yamamoto N, Takazawa K: Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: A preliminary study. J Med Food 2009;12:1221-1226.
28. Yamaguchi N, Kawaguchi K, Yamamoto N: Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur J Pharmacol 2009;620:71-77.
29. Mizuno S, Nishimura S, Matsuura, K, Gotou T, Yamamoto N: Release of short and praline-rich antihypertensive peptides from casein hydrolysate with an Aspergillus oryzae protease. J Dairy Sci 2004;87:183-188.